Aphexda (motixafortide) coverage for stem cell mobilization
Customize your policy alerts
Sign up for Geisinger Health Plan Policy MBP 315.0 alerts
Get alerted when Policy MBP 315.0 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization requirements for Aphexda (motixafortide) when used with filgrastim to mobilize hematopoietic stem cells for autologous transplantation across Geisinger Health Plan lines of business.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.